Perioperative Chemotherapy for Potentially Resectable Gastric Cancer
Status:
Completed
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
Stage I：Neoadjuvant therapy
- Tegafur，Gimeracil and Oteracil Potassium Capsules plus oxaliplatin is superior to
surgery alone;Capecitabine plus oxaliplatin is non-inferiority to Tegafur，Gimeracil and
Oteracil Potassium Capsules plus oxaliplatin
Stage II: Perioperative therapy
- Perioperative Tegafur，Gimeracil and Oteracil Potassium Capsules plus oxaliplatin is
superior to adjuvant Tegafur，Gimeracil and Oteracil Potassium Capsules plus oxaliplatin
alone;Capecitabine plus oxaliplatin regimen is noninferiority to Tegafur,Gimeracil and
Oteracil Potassium Capsules plus oxaliplatin
- A regimen of Tegafur，Gimeracil and Oteracil Potassium Capsules plus oxaliplatin(SOX) and
Capecitabine plus oxaliplatin(XELOX) improves survival among patients with incurable
locally advanced or metastatic gastric cancer. The investigators assessed whether the
addition of a perioperative regimen of SOX or XELOX regimen to adjuvant alone improves
R0 resection rate and survival among patients with curable locally advanced gastric
cancer.